DHP Korea Co. Ltd (131030) - Net Assets
Based on the latest financial reports, DHP Korea Co. Ltd (131030) has net assets worth ₩150.47 Billion KRW (≈ $101.97 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩175.59 Billion ≈ $119.00 Million USD) and total liabilities (₩25.12 Billion ≈ $17.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 131030 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩150.47 Billion |
| % of Total Assets | 85.69% |
| Annual Growth Rate | 9.79% |
| 5-Year Change | 20.9% |
| 10-Year Change | 119.49% |
| Growth Volatility | 5.15 |
DHP Korea Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how DHP Korea Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is DHP Korea Co. Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for DHP Korea Co. Ltd (2014–2024)
The table below shows the annual net assets of DHP Korea Co. Ltd from 2014 to 2024. For live valuation and market cap data, see market cap of DHP Korea Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩143.73 Billion ≈ $97.41 Million |
+6.91% |
| 2023-12-31 | ₩134.45 Billion ≈ $91.12 Million |
+8.02% |
| 2022-12-31 | ₩124.47 Billion ≈ $84.35 Million |
-2.01% |
| 2021-12-31 | ₩127.02 Billion ≈ $86.08 Million |
+6.85% |
| 2020-12-31 | ₩118.88 Billion ≈ $80.57 Million |
+10.34% |
| 2019-12-31 | ₩107.75 Billion ≈ $73.02 Million |
+13.54% |
| 2018-12-31 | ₩94.90 Billion ≈ $64.31 Million |
+9.64% |
| 2017-12-31 | ₩86.55 Billion ≈ $58.66 Million |
+15.01% |
| 2016-12-31 | ₩75.26 Billion ≈ $51.00 Million |
+14.92% |
| 2015-12-31 | ₩65.49 Billion ≈ $44.38 Million |
+15.92% |
| 2014-12-31 | ₩56.49 Billion ≈ $38.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DHP Korea Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 697.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩103.98 Billion | 72.34% |
| Common Stock | ₩8.28 Billion | 5.76% |
| Other Components | ₩31.47 Billion | 21.90% |
| Total Equity | ₩143.73 Billion | 100.00% |
DHP Korea Co. Ltd Competitors by Market Cap
The table below lists competitors of DHP Korea Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Les Docks des Pétroles d'Ambès -SA
PA:DPAM
|
$92.91 Million |
|
Manoj Vaibhav Gems 'N' Jewellers Limited
NSE:MVGJL
|
$92.94 Million |
|
Kabra Extrusion Technik Limited
NSE:KABRAEXTRU
|
$92.95 Million |
|
Lakeland Industries Inc
NASDAQ:LAKE
|
$92.96 Million |
|
Strix Group Plc
F:SG9
|
$92.84 Million |
|
Daesung Holdin
KO:016710
|
$92.84 Million |
|
Seanergy Maritime Holdings Corp
F:RHSR
|
$92.81 Million |
|
ATM Grupa S.A.
WAR:ATG
|
$92.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DHP Korea Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 134,450,876,220 to 143,734,917,510, a change of 9,284,041,290 (6.9%).
- Net income of 10,308,425,360 contributed positively to equity growth.
- Dividend payments of 1,525,924,200 reduced retained earnings.
- Share repurchases of 117,566,710 reduced equity.
- New share issuances of 117,566,700 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩10.31 Billion | +7.17% |
| Dividends Paid | ₩1.53 Billion | -1.06% |
| Share Repurchases | ₩117.57 Million | -0.08% |
| Share Issuances | ₩117.57 Million | +0.08% |
| Other Changes | ₩501.54 Million | +0.35% |
| Total Change | ₩- | 6.91% |
Book Value vs Market Value Analysis
This analysis compares DHP Korea Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.94x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4609.90 | ₩8960.00 | x |
| 2017-12-31 | ₩5301.97 | ₩8960.00 | x |
| 2018-12-31 | ₩5813.33 | ₩8960.00 | x |
| 2019-12-31 | ₩6600.21 | ₩8960.00 | x |
| 2020-12-31 | ₩7411.07 | ₩8960.00 | x |
| 2021-12-31 | ₩7918.38 | ₩8960.00 | x |
| 2022-12-31 | ₩8207.04 | ₩8960.00 | x |
| 2023-12-31 | ₩8811.11 | ₩8960.00 | x |
| 2024-12-31 | ₩9403.11 | ₩8960.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DHP Korea Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.17%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.59%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.16x
- Recent ROE (7.17%) is below the historical average (11.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 16.85% | 29.23% | 0.48x | 1.19x | ₩3.87 Billion |
| 2015 | 15.73% | 26.71% | 0.53x | 1.12x | ₩3.75 Billion |
| 2016 | 15.28% | 25.71% | 0.53x | 1.11x | ₩3.97 Billion |
| 2017 | 14.88% | 25.86% | 0.53x | 1.09x | ₩4.22 Billion |
| 2018 | 10.54% | 20.16% | 0.48x | 1.09x | ₩512.62 Million |
| 2019 | 13.55% | 24.15% | 0.51x | 1.10x | ₩3.82 Billion |
| 2020 | 12.12% | 23.68% | 0.47x | 1.09x | ₩2.52 Billion |
| 2021 | 7.79% | 17.26% | 0.41x | 1.10x | ₩-2.81 Billion |
| 2022 | 4.03% | 8.54% | 0.43x | 1.09x | ₩-7.43 Billion |
| 2023 | 8.00% | 14.86% | 0.48x | 1.11x | ₩-2.68 Billion |
| 2024 | 7.17% | 12.59% | 0.49x | 1.16x | ₩-4.07 Billion |
Industry Comparison
This section compares DHP Korea Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $440,493,390,371
- Average return on equity (ROE) among peers: 2.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DHP Korea Co. Ltd (131030) | ₩150.47 Billion | 16.85% | 0.17x | $92.87 Million |
| Dongwha Pharm.Co.Ltd (000020) | $360.13 Billion | 4.96% | 0.24x | $112.70 Million |
| Yuhan Corp. (000100) | $1.07 Trillion | 11.67% | 0.17x | $4.51 Billion |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $58.60 Million |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $90.54 Billion | 5.22% | 0.52x | $17.71 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.97 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $74.84 Million |
| Samil Pharm (000520) | $55.42 Billion | -20.19% | 0.95x | $132.07 Million |
| Donga Socio Holdings (000640) | $190.87 Billion | 12.43% | 2.11x | $429.77 Million |
| Jw Pharmac (001060) | $225.76 Billion | 14.13% | 1.78x | $469.14 Million |
About DHP Korea Co. Ltd
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company… Read more